Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder

Medytox

Status and phase: Completed; Phase 1

Conditions: Overactive Bladder

Treatments: Drug: Botox; Drug: Meditoxin

Study type: Interventional

Funder types: Industry

Identifiers

NCT03371342

MT01-KR17OAB101

Details and patient eligibility

About

To investigate the safety of MEDITOXIN in female subjects with idiopathic overactive bladder compared with BOTOX

Enrollment: 30 patients

Sex: Female

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female aged more than 20 years
• Subject who has symptoms of Overactive Bladder for a period of at least 6 months immediately prior to screening

Exclusion criteria

• Patient not appropriate for participating in this study according to the investigator's opinion

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

30 participants in 2 patient groups

MEDITOXIN

Experimental group

Treatment:

Drug: Meditoxin

BOTOX

Active Comparator group

Treatment:

Drug: Botox